This Plain Language Summary of Publication article (PLSP) from Future Rare Diseases tested verducatib (formerly BI 1291583) in 322 adults with bronchiectasis who had experienced frequent exacerbations requiring antibiotics. Participants received either low, medium, or high doses of verducatib or placebo pills to determine the drug’s effectiveness, safety, and optimal dosing for bronchiectasis treatment.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding study’ and was published in the European Respiratory Journal.

Visit ERS Publications using the link to read the original article.